WO2006063452B1 - Ex vivo verification of biopsy tissue samples - Google Patents

Ex vivo verification of biopsy tissue samples

Info

Publication number
WO2006063452B1
WO2006063452B1 PCT/CA2005/001904 CA2005001904W WO2006063452B1 WO 2006063452 B1 WO2006063452 B1 WO 2006063452B1 CA 2005001904 W CA2005001904 W CA 2005001904W WO 2006063452 B1 WO2006063452 B1 WO 2006063452B1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
spectroscopy
signal
approximation
destructive
Prior art date
Application number
PCT/CA2005/001904
Other languages
French (fr)
Other versions
WO2006063452A1 (en
Inventor
Olga Pawluczyk
Cameron Piron
Original Assignee
Olga Pawluczyk
Cameron Piron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olga Pawluczyk, Cameron Piron filed Critical Olga Pawluczyk
Publication of WO2006063452A1 publication Critical patent/WO2006063452A1/en
Publication of WO2006063452B1 publication Critical patent/WO2006063452B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
    • G01N29/44—Processing the detected response signal, e.g. electronic circuits specially adapted therefor
    • G01N29/46—Processing the detected response signal, e.g. electronic circuits specially adapted therefor by spectral analysis, e.g. Fourier analysis or wavelet analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
    • G01N29/04—Analysing solids
    • G01N29/06—Visualisation of the interior, e.g. acoustic microscopy
    • G01N29/0654—Imaging
    • G01N29/0672—Imaging by acoustic tomography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
    • G01N29/44—Processing the detected response signal, e.g. electronic circuits specially adapted therefor
    • G01N29/449—Statistical methods not provided for in G01N29/4409, e.g. averaging, smoothing and interpolation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2291/00—Indexing codes associated with group G01N29/00
    • G01N2291/02—Indexing codes associated with the analysed material
    • G01N2291/024—Mixtures
    • G01N2291/02466—Biological material, e.g. blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2291/00—Indexing codes associated with group G01N29/00
    • G01N2291/02—Indexing codes associated with the analysed material
    • G01N2291/024—Mixtures
    • G01N2291/02475—Tissue characterisation

Abstract

A method for confirming the presence of abnormal tissues within an ex vivo sample of tissue comprising non-destructively observing the removed sample for the presence of a contrasting agent, which has been previously administered to the patient, wherein the contrasting agent accumulates in abnormal tissues.

Claims

AMENDED CLAIMS received by the International Bureau on 23 June 2006 (23.06.2006)+ STATEMENT
1. A method for indicating a likely presence of abnormal tissue within an ex vivo sample of tissue comprising: providing observable agent to an in vivo region of interest of a patient; removing from the patient a tissue sample from the region of interest to provide a removed tissue sample; non-destructively, or minimally-destructively observing the removed tissue samples under conditions that allow observation or detection of the agent; and evaluating results of the observation or detection of the observable agent within the removed tissue sample to confirm that tissue was removed from a patient that had been provided with the observable agent in vivo.
2. The method of claim 1 wherein non-destructive or minimally destructive observing of the removed tissue evaluates concentrations of the observable agent within the tissue to confirm that tissue had been removed from the region of interest.
3. The method of claim 2 wherein evaluating results comprises assessing a likelihood of the presence of abnormal tissue within a sample.
4. The method of claim 2 wherein evaluating results comprises assessing whether the removed tissue sample has been taken from the region of interest.
5. The method of claim 2 wherein non-destructively observing comprises spectroscopic analysis.
6. The method of claim 2 wherein after evaluating results, histopathic examination is performed on the removed tissue sample.
7. The method of claim 2 wherein the non-destructive or minimally destructive observing comprises at least one procedure selected from the group consisting of colorimetry, sonography, spectroscopy, and magnetic resonance imaging of the removed tissue sample.
34
8. The method of claim 7 wherein the spectroscopy is selected from the group consisting of scattered radiation spectroscopy, frustrated total internal reflection spectroscopy, Raman spectroscopy, fluorescent spectroscopy, emission spectroscopy, Fourier transform spectroscopy, flame spectroscopy, laser excited emission spectroscopy, mass spectroscopy, Auger spectroscopy, magnetic resonance spectroscopy.
9. The method of claim 8 where intensity changes or density differences from the removed tissue sample provide information that is evaluated.
10. The method of claim 2 wherein the observable agent is known to be absorbed differently by normal tissue and abnormal tissue.
11. The method of claim 2 wherein non-destructive observation is used and the nondestructive observation comprises assessing concentration of the observable agent in the tissue by measuring or detection of absorption of electromagnetic radiation at at least one preselected wavelength or one or more spectral bands in at least one of the UV, visible and IR spectral ranges without the damage to the tested tissue
12. The method of claim 2 wherein a non-destructive observation is used and the non-destructive observation comprises concentration measuring techniques.
13. The method of claim 2 wherein evaluating results includes treatment of obtained measurement or observation data by at least one data approximation technique selected from the group consisting of hnear approximation, quadratic and any higher order approximation, polynomial approximation and spline approximation.
14. The method of claim 2 wherein the evaluating of results comprises approximating concentration of the observable agent in the removed tissue sample.
35
15. The method of claim 14 wherein approximating concentration comprises a step of absorption spectroscopy in at least one of the ultraviolet, visible and infrared spectral ranges.
16. The method of claim 15 wherein the absorption spectroscopy comprises concentration measurement of the observable agent in the removed tissue sample applying spectroscopy at selected wavelengths of one or more continuous spectral bands of radiation scattered by the removed tissue sample.
17. The method of claim 2 wherein evaluating results includes treatment of obtained data by at least one signal processing technique selected from the group consisting of: instrument calibration, dark signal subtraction, signal normalization for integration time, signal averaging, filtration, noise reduction, signal enhancement, signal smoothing, using linear approximation, quadratic and any higher order polynomial approximation, spline approximation, differentiation, integration, first or higher order derivative calculation, averaging over any number of points or measurements, subtraction of unnecessary information, signal segmentation, or other manipulation of data to improve the qualities of the signal to be analyzed.
18. The method of claim 2 wherein evaluating results includes the analysis of obtained data by at least one signal analysis technique selected from the group consisting of: partial least square regression, principal component analysis, neural networks, wavelet transforms, clustering, genetic algorithms, Monte Carlo methods, mathematical simulation of noise or errors, signal standardization using any approximation method, photometric signal correction for offset, dark noise contribution, response non-linearity, smoothing, averaging, derivative calculation, integration, or other manipulation of data to improve the extraction of information from the observed signal.
19 A system for indicating a likely presence of abnormal tissue within an ex vivo sample of tissue comprising: an imaging system for observing a region of tissue within a patient; at least one observable agent that can be delivered to a region of interest of a patient; a tissue removing device that may be used within the imaging system; a system for non-destructively or minimally destructively observing removed tissue samples under conditions that allow observation or detection of the observable agent; and a data storage system or processor that receives data from the system for non- destructively or minimally destructively observing removed tissue to confirm that tissue was removed from a patient that had been provided with the observable agent in vivo.
20. The system of claim 19 wherein only non-destructive observing of the removed tissue is performed.
37
PCT/CA2005/001904 2004-12-16 2005-12-16 Ex vivo verification of biopsy tissue samples WO2006063452A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/014,675 2004-12-16
US11/014,675 US7854705B2 (en) 2004-12-16 2004-12-16 Ex vivo verification of biopsy tissue samples

Publications (2)

Publication Number Publication Date
WO2006063452A1 WO2006063452A1 (en) 2006-06-22
WO2006063452B1 true WO2006063452B1 (en) 2006-08-10

Family

ID=36587493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2005/001904 WO2006063452A1 (en) 2004-12-16 2005-12-16 Ex vivo verification of biopsy tissue samples

Country Status (2)

Country Link
US (1) US7854705B2 (en)
WO (1) WO2006063452A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154277A1 (en) * 2002-12-31 2005-07-14 Jing Tang Apparatus and methods of using built-in micro-spectroscopy micro-biosensors and specimen collection system for a wireless capsule in a biological body in vivo
EP1978485A1 (en) * 2005-05-13 2008-10-08 Tripath Imaging, Inc. Methods of chromogen separation-based image analysis
JP2008043396A (en) * 2006-08-11 2008-02-28 Olympus Corp Endoscope system
JP2008148791A (en) * 2006-12-14 2008-07-03 Olympus Corp Endoscope system
US7792379B2 (en) * 2007-02-06 2010-09-07 Accenture Global Services Gmbh Transforming a submitted image of a person based on a condition of the person
CN102015020A (en) * 2008-05-09 2011-04-13 休·贝克曼 Medical device for diagnosing and treating anomalous tissue and method for doing the same
US9492130B2 (en) 2010-11-24 2016-11-15 Hologic, Inc. System for improved tissue-handling and in line analysis of the tissue
US20130003044A1 (en) * 2010-12-14 2013-01-03 Chemlmage Corporation System and Method for Raman Based Chronic Exposure Detection
US9786047B2 (en) * 2011-05-18 2017-10-10 Nec Corporation Information processing system, method, and apparatus supporting a pathological diagnosis, and control method and control program thereof
US9557281B2 (en) 2011-06-09 2017-01-31 The Regents Of The University Of California Excised specimen imaging using a combined PET and micro CT scanner
JP5426620B2 (en) * 2011-07-25 2014-02-26 富士フイルム株式会社 Endoscope system and method for operating endoscope system
JP6687524B2 (en) 2014-01-30 2020-04-22 ビーディー キエストラ ベスローテン フェンノートシャップ System and method for image acquisition using supervised high quality imaging
WO2015134668A1 (en) * 2014-03-04 2015-09-11 The Regents Of The University Of California Automated quality control of diagnostic radiology
WO2015134277A1 (en) 2014-03-05 2015-09-11 Faxitron Bioptics, Llc System and method for multi-axis imaging of specimens
US20160178519A1 (en) * 2014-12-23 2016-06-23 Boston Scientific Scimed, Inc. Marker For Detection And Confirmation Of Peripheral Lung Nodules
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
US9883854B2 (en) * 2015-04-08 2018-02-06 Synaptive Medical (Barbados) Inc. Systems, devices and methods for tissue removal and analysis
WO2017040977A1 (en) 2015-09-04 2017-03-09 Faxitron Bioptics, Llc Multi-axis specimen imaging device with embedded orientation markers
US10743848B2 (en) 2015-09-25 2020-08-18 The Regents Of The University Of Michigan Biopsy device for coherent Raman imaging
WO2018085719A1 (en) 2016-11-04 2018-05-11 Hologic, Inc. Specimen radiography system
CN106901696B (en) * 2017-02-23 2019-11-05 马青山 A kind of cancer site prediction auxiliary device
US11317881B2 (en) 2017-09-11 2022-05-03 Faxitron Bioptics, Llc Imaging system with adaptive object magnification
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
WO2022060566A1 (en) * 2020-09-16 2022-03-24 Hologic, Inc. Systems and methods for confirming tissue specimens removed using contrast-enhanced x-ray imaging
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4930516B1 (en) * 1985-11-13 1998-08-04 Laser Diagnostic Instr Inc Method for detecting cancerous tissue using visible native luminescence
NO884565L (en) * 1987-10-15 1989-04-17 Univ Moskovsk PREPARATION FOR DISPOSITION OF DIAGNOSIS OF DEPARTURED NEOPLASMA.
WO1990006718A1 (en) * 1988-12-21 1990-06-28 Massachusetts Institute Of Technology A method for laser induced fluorescence of tissue
US6723303B1 (en) * 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
GB9314499D0 (en) * 1993-07-12 1993-08-25 Nycomed Imaging As Method
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6091985A (en) * 1998-01-23 2000-07-18 Research Foundation Of City College Of New York Detection of cancer and precancerous conditions in tissues and/or cells using native fluorescence excitation spectroscopy
US6066102A (en) * 1998-03-09 2000-05-23 Spectrascience, Inc. Optical biopsy forceps system and method of diagnosing tissue
US6174291B1 (en) * 1998-03-09 2001-01-16 Spectrascience, Inc. Optical biopsy system and methods for tissue diagnosis
US6411838B1 (en) * 1998-12-23 2002-06-25 Medispectra, Inc. Systems and methods for optical examination of samples
US6167297A (en) 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
AU779946B2 (en) 1999-10-18 2005-02-17 Institute For Magnetic Resonance Research Magnetic resonance spectroscopy of breast biopsy to determine pathology, vascularization and nodal involvement
EP1259163A4 (en) * 2000-02-08 2006-05-03 Cornell Res Foundation Inc Multiphoton excitation through optical fibers for fluorescence spectroscopy
AU2001251114A1 (en) * 2000-03-28 2001-10-08 Board Of Regents, The University Of Texas System Enhancing contrast in biological imaging
US6841388B2 (en) * 2000-12-05 2005-01-11 Vysis, Inc. Method and system for diagnosing pathology in biological samples by detection of infrared spectral markers
US6697652B2 (en) * 2001-01-19 2004-02-24 Massachusetts Institute Of Technology Fluorescence, reflectance and light scattering spectroscopy for measuring tissue
GB0103030D0 (en) * 2001-02-07 2001-03-21 Univ London Spectrum processing and processor
US7769426B2 (en) * 2002-04-23 2010-08-03 Ethicon Endo-Surgery, Inc. Method for using an MRI compatible biopsy device with detachable probe
NO20025711D0 (en) 2002-11-27 2002-11-27 Amersham Health As Magnetic resonance method
US20040254445A1 (en) * 2003-06-13 2004-12-16 Craig Bittner Use of MRI to screen individuals for prostate cancer

Also Published As

Publication number Publication date
WO2006063452A1 (en) 2006-06-22
US20060173266A1 (en) 2006-08-03
US7854705B2 (en) 2010-12-21

Similar Documents

Publication Publication Date Title
WO2006063452B1 (en) Ex vivo verification of biopsy tissue samples
Ellis et al. Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy
Mistek et al. Race differentiation by Raman spectroscopy of a bloodstain for forensic purposes
US8014569B2 (en) Method and apparatus for performing qualitative and quantitative analysis of produce (fruit, vegetables) using spatially structured illumination
Mehdizadeh et al. An intelligent system for egg quality classification based on visible-infrared transmittance spectroscopy
CN101137322B (en) Method and apparatus for measuring cancerous changes from reflectance spectral measurements obtained during endoscopic imaging
US6983176B2 (en) Optically similar reference samples and related methods for multivariate calibration models used in optical spectroscopy
Xia et al. Characterizing beef muscles with optical scattering and absorption coefficients in VIS-NIR region
Thumanu et al. Diagnosis of liver cancer from blood sera using FTIR microspectroscopy: a preliminary study
Nicolaï et al. Nondestructive evaluation: Detection of external and internal attributes frequently associated with quality and damage
US10746706B2 (en) Photoacoustic physio-chemical tissue analysis
Kendall et al. Exploiting the diagnostic potential of biomolecular fingerprinting with vibrational spectroscopy
Camerlingo et al. Wavelet data processing of micro-Raman spectra of biological samples
JP7013376B2 (en) Methods, computer programs, and systems for analyzing samples, including identifying cells by the FTIR spectrum generated by each cell.
WO2016201572A1 (en) Methods of detection of steatosis
Sinica et al. Raman spectroscopic discrimination of normal and cancerous lung tissues
Ridder et al. Noninvasive alcohol testing using diffuse reflectance near-infrared spectroscopy
Ralbovsky et al. Diagnosis of a model of Duchenne muscular dystrophy in blood serum of mdx mice using Raman hyperspectroscopy
WO2021210642A1 (en) Hemoglobin concentration measuring system, transvaginal probe, attachment, and hemoglobin concentration measuring method
Matousek et al. Recent advances in pharmaceutical analysis using transmission Raman spectroscopy
Sablinskas et al. Fiber attenuated total reflection infrared spectroscopy of kidney tissue during live surgery
Le Corvec et al. Fast and non-invasive medical diagnostic using mid infrared sensor: the AMNIFIR project
Hiremath et al. Novel insights into tissue-specific biochemical alterations in pediatric eosinophilic esophagitis using raman spectroscopy
CN114424048B (en) Evidence obtaining detector and system thereof
Goodacre et al. Clinical Spectroscopy: general discussion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05820787

Country of ref document: EP

Kind code of ref document: A1